The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed Andrew Gerry

Dated 31 August 2001

Patents Form 1/77

Patents Act 1977
(Rule 16)

The Patent Office

1/77

THE PATENT OFFICE
The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH
10 NOV 2000

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference — 86.87.74346

2. Patent application number *(The Patent Office will fill in this part)* — **0027552.9**

3. Full name, address and postcode of the or of each applicant *(underline all surnames)*

Boehringer Ingelheim Pharma KG
Binger Strasse 173
D-55216 Ingelheim am Rhein
Germany

13NOV00 E582976-2 D00027
P01/7700 0.00-0027552.9

Patents ADP number *(if you know it)*

If the applicant is a corporate body, give country/state of incorporation

7542335001

4. Title of the invention — Anti-tumor compounds

5. Name of your agent *(if you have one)* — Frank B. Dehn & Co.

"Address for service" in the United Kingdom to which all correspondence should be sent *(including the postcode)*

179 Queen Victoria Street
London
EC4V 4EL

Patents ADP number *(if you know it)* — 166001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and *(if you know it)* the or each application number

Country	Priority application number *(if you know it)*	Date of filing *(day / month / year)*

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing *(day / month / year)*

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? *(Answer 'Yes' if:*

a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or
c) any named applicant is a corporate body.
See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	
Description	40
Claim(s)	9
Abstract	1
Drawing(s)	

10. If you are also filing any of the following, state how many against each item.

Priority documents	
Translations of priority documents	
Statement of inventorship and right to grant of a patent *(Patents Form 7/77)*	
Request for preliminary examination and search *(Patents Form 9/77)*	
Request for substantive examination *(Patents Form 10/77)*	
Any other documents *(please specify)*	

11. I/We request the grant of a patent on the basis of this application.

Signature Frank B Dehn & Co Date 10 November 2000

12. Name and daytime telephone number of person to contact in the United Kingdom

C.P. Pett
01273 244200

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

a) *If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.*
b) *Write your answers in capital letters using black ink or you may type them.*
c) *If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s) of the form. Any continuation sheet should be attached to this form.*
d) *If you have answered 'Yes', Patents Form 7/77 will need to be filed.*
e) *Once you have filled in the form you must remember to sign and date it.*
f) *For details of the fee and ways to pay please contact the Patent Office.*

Anti-tumor compounds

Field of the invention

The present invention relates to the field of tumor treatment by administration of a prodrug that is converted into a drug at the site of tumor. In particular, the invention relates to anti-tumor compounds in the form of prodrugs which may be converted into a drug by the catalytic action of FAPα, and to their manufacture and pharmaceutical use.

Background and prior art

The human fibroblast activation protein (FAPα) is a M_r 95,000 cell surface molecule originally identified with monoclonal antibody (mAb) F19 (Rettig *et al.* (1988) *Proc. Natl. Acad. Sci. USA* **85**, 3110-3114; Rettig *et al.* (1993) *Cancer Res.* **53**, 3327-3335). The FAPα cDNA codes for a type II integral membrane protein with a large extracellular domain, trans-membrane segment, and short cytoplasmic tail (Scanlan *et al.* (1994) *Proc. Natl. Acad. Sci. USA* **91**, 5657-5661; WO 97/34927). FAPα shows 48 % amino acid sequence identity to the T-cell activation antigen CD26, also known as dipeptidyl peptidase IV (DPPIV; EC 3.4.14.5), a membrane-bound protein with dipeptidyl peptidase activity (Scanlan *et al.*, *loc. cit.*). FAPα has enzymatic activity and is a member of the serine protease family, with serine 624 being critical for enzymatic function (WO 97/34927). Work using a membrane overlay assay revealed that FAPα dimers are able to cleave Ala-Pro-7-amino-4-trifluoromethyl coumarin, Gly-Pro-7-amino-4-trifluoromethyl coumarin, and Lys-Pro-7-amino-4-trifluoromethyl coumarin dipeptides (WO 97/34927).

FAPα is selectively expressed in reactive stromal fibroblasts of many histological types of human epithelial cancers, granulation tissue of healing wounds, and malignant cells of certain bone and soft tissue sarcomas. Normal adult tissues are generally devoid of detectable FAPα, but some foetal mesenchymal tissues transiently express the molecule. In contrast,

most of the common types of epithelial cancers, including >90% of breast, non-small-cell lung, and colorectal carcinomas, contain FAPα-reactive stromal fibroblasts (Scanlan *et al.*, *loc. cit.*). These $FAP\alpha^+$ fibroblasts accompany newly formed tumor blood vessels, forming a distinct cellular compartment interposed between the tumor capillary endothelium and the basal aspect of malignant epithelial cell clusters (Welt *et al.* (1994) *J. Clin. Oncol.* 12(6), 1193-1203). While $FAP\alpha^+$ stromal fibroblasts are found in both primary and metastatic carcinomas, the benign and premalignant epithelial lesions tested (Welt et al., loc. cit.), such as fibroadenomas of the breast and colorectal adenomas, only rarely contain $FAP\alpha^+$ stromal cells. Based on the restricted distribution pattern of FAPα in normal tissues and its uniform expression in the supporting stroma of many malignant tumors, clinical trials with ^{131}I-labeled mAb F19 have been initiated in patients with metastatic colon carcinomas (Welt *et al.*, *loc. cit.*).

For new cancer therapies based on cytotoxic or cytostatic drugs, a major consideration is to increase the therapeutic index by improving the efficacy of cancerous tissue killing and/or reducing the toxicity for normal tissue of the cytotoxic or cytostatic agents. To increase specificity of tumor tissue killing and reduce toxicity in normal tissues, trigger mechanisms can be designed so that the toxic agents synthesised in their prodrug or inactive forms are rendered active when and where required, notably in the cancerous tissues (Panchal (1998) *Biochem. Pharmacol.* **55**, 247-252). Triggering mechanisms may include either exogenous factors such as light or chemicals or endogenous cellular factors, such as enzymes with restricted expression in cancer tissues. Another concept, that has been further elaborated, is called 'antibody-directed enzyme prodrug therapy' (ADEPT) or 'antibody-directed catalysis' (ADC) (Huennekens (1994) *Trends Biotechnol.* **12**, 234-239; Bagshawe (1994) *Clin. Pharmacokinet.* **27**, 368-376; Wang *et al.* (1992) *Cancer Res.* **52**, 4484-4491; Sperker *et al.* (1997) *Clin. Pharmacokinet.* 33(1), 18-31). In ADEPT, an antibody directed at a tumor-associated antigen is used to target a specific enzyme to the tumor site. The tumor-located enzyme converts a subsequently administered prodrug into an active cytotoxic agent. The antibody-enzyme conjugate (AEC) binds to a target antigen on cell membranes or to free antigen in extracellular fluid (ECF). A time interval between giving the AEC and prodrug allows for the AEC to be cleared from normal tissues so that the prodrug is not activated in the normal tissues or blood. However, some disadvantages of ADEPT are related to the properties of the AEC (Bagshawe, *loc. cit.*). For example, in humans, only a small fraction

of the administered dose of the targeting AEC binds to tumor tissue and the remainder is distributed through body fluids from which it is cleared with significant time delays. Even very low concentrations of unbound enzyme can catalyse enough prodrug to have toxic effects because plasma and normal ECF volumes are much greater than those of tumor ECF. The AEC may also be immunogenic, thus preventing repeat administration, in many instances.

The International patent applications WO 97/12624 and WO 97/14416 disclose oligopeptides including the following penta- and hexapeptide (SEQ.ID.NOs.: 151 and 177: hArg-Tyr-Gln-Ser-Ser-Pro; hArg-Tyr-Gln-Ser-Pro;), comprising amino acid sequences, which are recognized and proteolytically cleaved by free prostate specific antigen (PSA) and therapeutic agents which comprise conjugates of such oligopeptides and known therapeutic or cytotoxic agents. These oligopeptide conjugates which comprise at least one glutamine-serine moiety are useful for treatment of prostate cancer only.

The problem underlying the present invention was to provide methods and means for improving normal tissue tolerability of cytotoxic or cytostatic agents with known efficacy against a broad range of tumor tissues, which can be administered to patients in need thereof in a safe and convenient way.

Disclosure of the invention

In one aspect, therefore, the present invention relates to enzyme-activated anti-tumor compounds. In particular, the invention provides prodrugs which are capable of being converted into a cytotoxic or cytostatic drug, by the catalytic action of FAPα, said prodrugs exhibit an oligomeric part comprising up to 13 amino carboxylic residues, the C-terminal amino carboxylic thereof is recognised by FAPα, and a cytotoxic or cytostatic part, wherein the N-terminal amino function of the oligomeric part is attached to a capping group (Cg) which is capable of enhancing the chemical stability of said prodrug under physiological conditions and the physical stability of an aqueous pharmaceutical formulations comprising said prodrug.

In the context of this invention, a "drug" shall mean a chemical compound that may be administered to humans or animals as an aid in the treatment of disease. In particular, a drug is an active pharmacological agent.

The term "cytotoxic compound" shall mean a chemical compound which is toxic to living cells, in particular a drug that destroys or kills cells. The term "cytostatic compound" shall mean a compound that suppresses cell growth and multiplication and thus inhibits the proliferation of cells. Examples for cytotoxic or cytostatic compounds suitable for the present invention are anthracycline derivatives such as doxorubicin, analogs of methotrexate such as methothrexate, pritrexime, trimetrexate or DDMP, melphalan, analogs of cisplatin such as cisplatin, JM216, JM335, bis(platinum) or carboplatin, analogs of purines and pyrimidines such as cytarbine, gemcitabine, azacitidine, 6-thioguanine, flurdarabine or 2-deoxycoformycin, and analogs of other chemotherapeutic agents such as 9-aminocamptothecin, D,L-aminoglutethimide, trimethoprim, pyrimethamine, mitomycin C, mitoxantrone, cyclophosphanamide, 5-fluorouracil, extramustine, podophyllotoxin, bleomycin or taxol.

A "prodrug" shall mean a compound that, on administration, must undergo chemical conversion by metabolic processes before becoming an active pharmacological agent. In particular, a prodrug is a precursor of a drug. In the context of the present invention, the prodrug is significantly less cytotoxic or cytostatic than the drug it is converted into upon the catalytic action of FAPα. The expert knows methods of determining cytotoxicity of a compound, see e.g. example 6 herein, or Mosmann ((1983) *J. Immun. Meth.* **65**, 55-63). Preferably, the prodrug is at least three times less cytotoxic as compared to the drug in an in vitro assay.

A "drug being cytostatic or cytotoxic under physiological conditions" shall mean a chemical compound which is cytostatic or cytotoxic in a living human or animal body, in particular a compound that kills cells or inhibits proliferation of cells within a living human or animal body.

A "prodrug having a cleavage site which is recognised by FAPα" shall mean a prodrug which can act as a substrate for the enzymatic activity of FAPα. In particular, the enzymatic

activity of FAPα can catalyse cleavage of a covalent bond of the prodrug under physiological conditions. By cleavage of this covalent bond, the prodrug is converted into the drug, either directly or indirectly. Indirect activation would be the case if the cleavage product of the FAPα catalysed step is not the pharmacologically active agent itself but undergoes a further reaction step, e.g. hydrolysis, to become active. More preferably, the cleavage site of the prodrug is specifically recognised by FAPα, but not by other proteolytic enzymes present in the human or animal body. Also preferably, the cleavage site is specifically recognised by FAPα, but not by proteolytic enzymes present in human or animal body fluids, especially plasma. In a particularly preferred embodiment, the prodrug is stable in plasma, other body fluids, or tissues, in which biologically active FAPα is not present or detectable. Preferably, in an *in vitro* assay as carried out in Example 7 herein, more than 50%, more preferably more than 80%, more preferably more than 90% of the prodrug are still present in a solution containing 10% (v/v) of human plasma after 8 h at 37°C. The cleavage site should most preferably be specific for FAPα. In a preferred embodiment, the cleavage site comprises a L-proline residue which is linked to a cytotoxic or cytostatic drug via an amide bond. An example of this class is a doxorubicin-peptide conjugate. FAPα may catalyse the cleavage of a peptidic bond between the C-terminal amino acid residue of the peptide, which is preferably L-proline, and the cytotoxic or cytostatic compound.

Preferred compounds show at least 10% conversion to free drug, under standard conditions listed below. More preferred are compounds that show at least 20% conversion to free drug, under standard conditions. Even more preferred are compounds that show at least 50% conversion to free drug, under standard conditions. In this context, standard conditions are defined as follows: Each compound is dissolved in 50 mM Hepes buffer, 150 mM NaCl, pH 7.2, at a final concentration of 5 µM and incubated with 100 ng CD8FAPα (see example 4) for 24 hours at 37 °C. Release of free drug by CD8FAPα is determined as described in example 5.

Preferably, the present invention relates to a compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof,

wherein

R^1 represents an amino alkanoyl or oligopeptidoyl group, the N-terminal amino function of which is attached to a capping group (Cg) which is capable of enhancing the chemical stability of said compound under physiological conditions and the physical stability of aqueous pharmaceutical formulations comprising said compound;

R^a and R^b together with the interjacent N-C group form an optionally substituted, optionally benzo- or cyclohexano-condensed 3- to 7-membered saturated or unsaturated heterocyclic ring, in which one or two CH_2 groups may also be replaced by NH, O or S;

R^3 represents H, C_1-C_6-alkyl, C_3-C_8-cycloalkyl, aryl or heteroaryl; and

Cyt' represents the residue of a cytotoxic or cytostatic compound.

Preferred are those compounds of formula I, wherein the capping group exhibits one or more functional groups, which have the capability of forming salts with pharmaceutially acceptable acids or bases, selected from amino, carboxy, phospate, phophonate, sulfate and sulfonate groups.

Particularly preferred are those compounds of formula I, wherein said capping group (Cg) is a group of formula

$$R^2\text{-}(CH_2)_m\text{-}Z\text{-},$$

in which

R^2 represents

(a) a group selected from C_1-C_6 alkyl, C_3-C_8 cycloalkyl, aryl and heteroaryl, wherein each of these groups is substituted by at least one amino, carboxy, phospate, phophonate, sulfate, sulfonate or hydroxy group, or

(b) an optionally substituted 5- to 7-membered saturated or unsaturated nitrogen, oxygen and/or sulfur containing heterocyclic group, or

(c) a phenyl group which is substituted by 1 to 5 fluorine atoms; or

(d) a C_1-C_6 fluoroalkyl group; or

(e) in the case that m is1, an optionally substituted 5- to 6-membered heteroaryl group;

Z represents –CO-, -O-CO-, -SO_2-, NH-CO-NH or a single bond;

m is 0 or 1.

Furthermore preferred are those compounds of formula I, wherein

R^1 represents a residue of formula Cg-A, Cg-B-A or Cg-$(D)_n$-B-A, in which

Cg represents a capping group of formula R^2-CH_2-Z-, wherein R^2 is an optionally substituted saturated heterocyclyl or heteroaryl group;

A, B and D each independently represent moieties derived from amino carboxylic acids of the formula -[NR^4-$(X)_p$-CO]- wherein X represents CR^5R^6 and wherein R^4, R^5 and R^6 each independently represent a hydrogen atom, an optionally substituted C_1-C_6-alkyl, C_3-C_8-cycloalkyl, aryl, aralkyl, heteroaryl or heteroarylalkyl group, and p is 1, 2, 3, 4, 5; or

A, B and D each independently represent moieties derived from cyclic amino carboxylic acids of formula



wherein

R^7 represents C_1-C_6-alkyl, OH, or NH_2,

n is an integer from 1 to 10;

q is 0, 1 or 2; and

r is 0, 1 or 2, in particular wherein

R^1 represents an aminoalkanoyl, or an oligopeptidoyl group, which is derived from glycine (Gly), or the D- or L-forms, in particular the (L)-configuration of alanine (Ala), valine (Val), leucine (Leu), isoleucine (Ile), phenylalanine (Phe), tyrosine (Tyr), tryptophan (Trp), cysteine (Cys), methionine (Met), serine (Ser), threonine (Thr), lysine (Lys), arginine (Arg), histidine (His), aspartic acid (Asp), glutamic acid (Glu), asparagine (Asn), glutamine (Gln), proline (Pro), 4-hydroxy-proline (Hyp), 5-hydroxy-lysine, norleucine (Nle), 5-hydroxynorleucine (Hyn), 6-hydroxynorleucine, ornithine, or cyclohexylglycine (Chg) and wherein the N-terminal amino function of said aminoalkanoyl or oligopeptidoyl group is attached to a capping group Cg, most preferably wherein the unit A is derived from L-proline, glycine, L-norleucine, L-cyclohexylglycine, L-5-hydroxynorleucine, L-6-hydroxynorleucine, L-5-hydroxylysine, L-arginine, or L-lysine.

Most preferred are the compounds of formula I, wherein R^1 is a group selected from the formulae (1) to (14):

Cg-Gly	(1)
Cg-Nle	(2)
Cg-Val	(3)
Cg-Met	(4)
Cg-Xxx-Gly	(5)
Cg-Xxx-Hyn	(6)
Cg-Xxx-Pro	(7)
Cg-Xxx-His	(8)
Cg-Xxx-Met	(9)
Cg-Xxx-Ala	(10)
Cg-Xxx-Hyn	(11)
Cg-Xxx-Ala-Gly	(12)
Cg-$(Xxx)_n$-Xxx-Gly	(13)
Cg-$(Xxx)_n$-Xxx-Ala-Gly	(14)

wherein

Cg represents a capping group selected from pyridinyloxycarbonyl, pyridinylacetyl, pyridinylmethylsulfonyl and pyridylmethylaminocarbonyl;

Xxx represents a moiety derived from an amino carboxylic acid; and

n is an integer from 1 to 6.

In another preferred embodiment of the present invention the heterocyclic ring formed by R^a, R^b and the interjacent N-C is substituted by R^8 and R^9, wherein R^8 and R^9 each independently represent a hydrogen or halogen atom or a C_1-C_6-alkyl, C_1-C_6-alkylamino, di-C_1-C_6-alkylamino, C_1-C_6-alkoxy, thiol, C_1-C_6-alkylthio, oxo, imino, fomyl, C_1-C_6-alkoxy carbonyl, amino carbonyl, C_3-C_8-cycloalkyl, aryl, or heteroaryl group.

Most preferred are the compounds of fomula IA



(IA)

wherein R^1, R^3, R^8, Cyt' are defined as hereinabove and hereinbelow, and X-Y represents CHR^9-CH_2, CR^2=CH, NH-CH_2, CH_2-NH, -CR^9-, CH_2-CHR^9-CH_2, in particular compounds of fomulae IA1 or IA2,



(IA1)



(IA2)

wherein R^3, Cyt' Cg, X and Yare as defined in any of the preceding claims, and R^{10} and R^{11} each independently represent a hydrogen atom, an optionally substituted C_1-C_6-alkyl, C_3-C_8-cycloalkyl, aryl or heteroaryl group or R^{10} and R^{11} together with the interjacent N-C group form an optionally substituted, optionally benzo- or cyclohexano-condensed 3- to 7-membered saturated or unsaturated heterocyclic ring, in which one or two CH_2 groups may also be replaced by NH, O or S.

In another preferred embodiment of the present invention R^2 represents a group selected from



In another preferred embodiment of the invention Cyt' is an anthracycline group.

Unless indicated otherwise, the simple stereoisomers as well as mixtures or racemates of the stereoisomers are included in the invention.

"C_1-C_6-alkyl" generally represents a straight-chained or branched hydrocarbon group having 1 to 6 carbon atoms.

The term "optionally substituted" as used hereinabove or hereinbelow with respect to a group or a moiety refers to a group or moiety which may optionally be substituted by one or more halogen atoms, hydroxyl, amino, C_1-C_6-alkyl-amino, di- C_1-C_6-alkyl-amino, C_1-C_6-alkyl-oxy, thiol, C_1-C_6-alkyl-thio, =O, =NH, -CHO, -COOH, -$CONH_2$, -$NHC(=NH)NH_2$, , C_3-C_8-cycloalkyl, aryl, or heteroaryl substituents , which may be identical to one another or different.

The following groups may be mentioned by way of example:

Methyl, ethyl, propyl, 1-methylethyl (isopropyl), butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl and 1-ethyl-2methyl-propyl, $HOCH_2$-, $CH_3CH(OH)$-, $CH_3CH(OH)CH_2CH_2$-, $HOCH_2CH_2CH_2CH_2$-, $H_2NCH_2CH_2CH_2$-, $H_2NCH_2CH_2CH_2CH_2$-, $H_2NCH_2CH(OH)CH_2CH_2$-, $H_2NC(=NH)NHCH_2CH_2CH_2$-, $HSCH_2$-, $CH_3SCH_2CH_2$-, $HOOCCH_2$-, $HOOCCH_2CH_2$-, $H_2NC(=O)CH_2$-, $H_2NC(=O)CH_2CH_2$-, benzyl, para-hydroxy-benzyl,



or



If a C_1-C_6-alkyl group is substituted, the substituents are preferably hydroxyl, amino, dimethylamino, diethylamino, thiol, methyl-thiol, methoxy, ethoxy, =O, =NH, -CHO, -COOH, $-COOCH_3$, $-COOCH_2CH_3$, $-CONH_2$, $-NHC(=NH)NH_2$, cyclohexyl, phenyl, benzyl, para-hydroxy-benzyl,



or



If C_1-C_6-alkyl is substituted with aryl or heteroaryl, C_1-C_6-alkyl is preferably C_1, more preferably a methylene group.

The terms "amino alkanoyl" and "oligopeptidoyl" including "di- or tripeptidoyl" as used hereinabove or hereinbelow with respect to group R^1 describe a group in which an amino

acid or an oligomer comprising up to 12, preferably 2 or 3 amino acid moieties is attached C-terminally to the nitrogen atom of the heterocyclic ring via an amide bond.

A person of ordinary skill in the chemistry of amino acids and oligopeptides will readily appreciate that certain amino acids may be replaced by other homologous, isosteric and/or isolectronic amino acids wherein the biological activity of the original amino acid or oligopeptide has been conserved upon modification. Certain unnatural and modified natural amino acids may also be utilized to replace the corresponding natural amino acid. Thus, for example, tyrosine may be replaced by 3-iodotyrosine, 2- or 3-methyltyrosine, 3-fluorotyrosine.

The term "capping group" as used hereinabove or hereinbelow with respect to a group which is attached to the N-terminal nitrogen atom of the amino alkanoyl or oligopeptidoyl group of group R^1 defines a group or moiety which reduces or eliminates the enzymatic degradation of the compounds of the present invention by the action of amino peptidases which are present in the blood plasma of warm blooded animals and enhances the physical stability of an aqueous pharmaceutical formulations comprising said prodrug.

"C_3-C_8-Cycloalkyl" generally represents a cyclic hydrocarbon group having 3 to 8 carbon atoms which may optionally be substituted by one or more hydroxyl, amino, C_1-C_6-alkyl-amino, di- C_1-C_6-alkyl-amino, C_1-C_6-alkyl, C_1-C_6-alkyloxy, thiol, C_1-C_6-alkyl-thio, =O, =NH, -CHO, -COOH, -$COOCH_3$, -$COOCH_2CH_3$, -$CONH_2$, -$NHC(=NH)NH_2$, or halogen substituents , which may be identical to one another or different.

"Heterocyclic ring" as used hereinabove and hereinbelow with respect to the group formed by R^a and R^b together with the interjacent N-C group generally represents a 3 to 7-membered, preferably 4-, 5- or 6-membered non-aromatic heterocyclic ring system, containing one nitrogen atom and optionally 1 or 2 additional heteroatoms selected from the group of nitrogen, oxygen and sulfur, which may be substituted by one or more halogen atoms or C_1-C_6-alkyl, C_1-C_6-alkylamino, di-C_1-C_6-alkylamino, C_1-C_6-alkoxy, thiol, C_1-C_6-alkylthio, oxo, imino, fomyl, C_1-C_6-alkoxy carbonyl, amino carbonyl, C_3-C_8-cycloalkyl, aryl, or heteroaryl groups, which may be identical to one another or different, and which optionally may be benzo- or cyclohexano-condensed. Such heterocyclic rings are prefe-

rably azetidine or are derived from a fully or partially hydrogenated pyrrole, pyridine, thiazole, isoxazole, pyrazole, imidazole, indole, benzimidazole, indazole, pyridazine, pyrimidine, pyrazin group. Most preferred are azetidine, pyrrolidine, 3,4-dehydropyrrolidine, piperidine, hexahydro-1H-azepine, octahydroindole, imidazolidine, thiazolidine.

If such heterocyclic ring is substituted, the substituents are preferably methyl, ethyl, propyl, 1-methylethyl (isopropyl), butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, hydroxyl, amino, dimethyl-amino, diethyl-amino, thiol, methyl-thiol, methoxy, ethoxy, -CHO, -COOH, $-COOCH_3$, $-COOCH_2CH_3$, or $-CONH_2$.

"Aryl" generally represents an aromatic ring system with 6 to 10, preferably 6 carbon atoms which may optionally be substituted by one or several hydroxyl, amino, C_1-C_6-alkyl-amino, di- C_1-C_6-alkyl-amino, C_1-C_6-alkyl, C_1-C_6-alkyloxy, thiol, C_1-C_6-alkyl-thio, -CHO, -COOH, $-COOCH_3$, $-COOCH_2CH_3$, $-CONH_2$, or halogen substituents, which may be identical to one another or different, and which optionally may be benzocondensed. Aryl substituents may be preferably derived form benzene, preferred examples being phenyl, 2-hydroxy-phenyl, 3-hydroxy-phenyl, 4-hydroxy-phenyl, 4-amino-phenyl, 2-amino-phenyl, 3-amino-phenyl.

If aryl is substituted, the substituents are preferably methyl, ethyl, propyl, 1-methylethyl (isopropyl), butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, hydroxyl, amino, dimethyl-amino, diethyl-amino, thiol, methyl-thiol, methoxy, ethoxy, -CHO, -COOH, $-COOCH_3$, $-COOCH_2CH_3$, or $-CONH_2$.

"Heteroaryl" generally represents a 5 to 10-membered aromatic heterocyclic ring system, containing 1 to 5 heteroatoms selected from the group of nitrogen, oxygen, or sulfur, which may optionally be substituted by one or several hydroxyl, amino, C_1-C_6-alkyl-amino, di-C_1-C_6-alkyl-amino, C_1-C_6-alkyl, C_1-C_6-alkyloxy, thiol, C_1-C_6-alkyl-thio, -CHO, -COOH, $-COOCH_3$, $-COOCH_2CH_3$, $-CONH_2$, or halogen substituents, which may be identical to one another or different, and which optionally may be benzocondensed. Heteroaryl substituents may preferably be derived from furane, pyrrole, thiophene, pyridine, thiazole, isoxazole, pyrazole, imidazole, benzofuran, thianaphthene, indole, benzimidazole, indazole, quino-

line, pyridazine, pyrimidine, pyrazine, chinazoline, pyrane, purine, adenine, guanine, thymine, cytosine, uracil.

If heteroaryl is substituted, the substituents are preferably methyl, ethyl, propyl, 1-methylethyl (isopropyl), butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, hydroxyl, amino, dimethyl-amino, diethyl-amino, thiol, methyl-thiol, methoxy, ethoxy, -CHO, -COOH, $-COOCH_3$, $-COOCH_2CH_3$, or $-CONH_2$.

"Residue of a cytotoxic or cytostatic compound" means that the compound H_2N-Cyt', which is released upon cleavage of the amide bond shown in formula (I), is either cytotoxic or cytostatic itself, or may be converted into a cytotoxic or cytostatic compound in a subsequent step.

In the latter case, -Cyt' may be a residue of formula -L-Cyt'', wherein L is a linker residue derived from a bifunctional molecule, for instance a diamine H_2N-L'-NH_2, an amino alcohol H_2N-L'-OH, for example p-amino-benzyl alcohol (PABOH), an amino carbonate, for example



or an unnatural amino carboxylic acid. If -Cyt' is of formula -L-Cyt'', the compound H_2N-L'-Cyt'' is generated by the enzymatic cleavage of the amide bond shown in formula (I). The compound H_2N-L'-Cyt'' may be cytotoxic or cytostatic itself or the linker residue cleaved off from Cyt'' in a subsequent step releasing the cytotoxic or cytostatic agent. For example, the compound H_2N-L'-Cyt'' may be hydrolysed under physiological conditions into a compound H_2N-L'-OH and the cytotoxic or cytostatic compound H-Cyt'', which is the active therapeutic agent (In the following, only the term Cyt' is used for both Cyt' and Cyt'', and only the term L is used for both L and L', for simplicity).

The pharmaceutically acceptable salts of the compounds of the present invention include the conventional non-toxic salts formed from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those from inorganic acids such as hy-

drochloric acid, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, maleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, oxalictrifluoroacetic and the like.

H_2N-Cyt' is preferably an anthracycline derivative of formula II



(II)

wherein

R^c represents C_1-C_6 alkyl, C_1-C_6 hydroxyalkyl or C_1-C_6 alkanoyloxy C_1-C_6 alkyl, in particular methyl, hydroxymethyl, diethoxyacetoxymethyl or butyryloxymethyl;

R^d represents hydrogen, hydroxy or C_1-C_6 alkoxy, in particular methoxy;

one of R^e and R^f represents a hydrogen atom; and the other represents a hydrogen atom or a hydroxy or tetrahydropyran-2-yloxy (OTHP) group.

Paricularly preferred are the following compounds of formula II:

R^c	R^d	R^e	R^f	Cyt
CH_2OH	OCH_3	H	OH	doxorubicin
CH_3	OCH_3	H	OH	daunorubicin
CH_2OH	OCH_3	OH	H	epirubicin
CH_3	H	H	OH	idarubicin
CH_2OH	OCH_3	H	OTHP	THP
CH_2OH	OCH_3	H	H	esorubicin
$CH_2OCOCH(OC_2H_5)_2$	OCH_3	H	OH	detorubicin
CH_2OH	H	H	OH	carminorubicin
$CH_2OCOC_4H_9$	OCH_3	H	OH	

Most preferred is doxorubicin (Dox). Other cytotoxic or cytostatic residues Cyt' may be derived for example from methotrexate, trimetrexate, pyritrexim, 5,10-dideazatetrahydrofolatepyrimetamine, trimethoprim, 10-propargyl-5,8-dideazafolate2,4-diamino-5(3',4'-dichlorophenyl)-6-methylpyrimidine, aminoglutethimide, goreserelin, melphalan, chlorambucil, analogs of other chemotherapeutic agents such as 9-aminocamtothecin (for examples see e.g. Burris HA, r. d. and S. M. Fields (1994). "Topoisomerase I inhibitors. An overview of the camptothecin analogs. [Review]." *Hematol. Oncol. Clin. North Am.* 8(2): 333-355; Iyer, L. and M. J. Ratain (1998). "Clinical pharmacology of camptothecins. [Review] [137 refs]." *Cancer Chemother. Pharmacol.* 42 Suppl: S31-S43.)

In formula (I), Cyt' may also be a biological effector molecule which either directly or indirectly effects destruction of tumor cells, like for example TNFα.

Preferred anthracycline prodrugs are the compounds of formula III



(III)

wherein R^a, R^b, R^c, R^d, R^e, R^f and R^l are as defined hereinabove.

Most preferred compounds of the invention are doxorubicin derivatives of formulae (IIIA) to (IIIF):



(IIIA)



(IIIB)



(IIIC)



(IIIE)



(IIIF)

If the part Cg-B-A or Cg-$(D)_m$-B-A of formula (I) contains two or more sulfur atoms, the compound of the invention may contain one or more disulfide bonds.

One class of cytotoxic or cytostatic compounds which may be used for the present invention has a primary amino function which is available for formation of an amidic bond as shown in formula (I), like doxorubicin. In this case, a linker molecule L is not necessary. If a cytostatic or cytotoxic compound does not have such an amino function, such a function may be created in such a compound by way of chemical modification, e.g. by introducing or converting a functional group or attaching a linker molecule to the compound. A linker molecule may also be inserted between the oligomeric part (i.e. the part comprising the amino carboxylic residues) and the cytostatic or cytotoxic part of the compound of the in-

vention to ensure or optimise cleavage of the amide bond between the oligomeric part and the cytotoxic or cytostatic part. If a linker molecule is present, i.e. in compounds containing the structure L-Cyt', the bond between L and Cyt' is preferably an amidic or ester bond. In a preferred embodiment, such a linker molecule is hydrolysed off the cytostatic or cytotoxic compound under physiological conditions after the enzymatic cleavage and thus the free cytostatic or cytotoxic compound is generated. In any case, the compound of the invention must have the property of being cleavable upon the catalytic action of FAPα and, as a direct or indirect consequence of this cleavage, releasing under physiological conditions a cytostatic or cytotoxic compound.

In a further aspect, the present invention relates to prodrug that is capable of being converted into a cytotoxic or cytostatic drug, by the catalytic action of FAPα, said prodrug exhibits an oligomeric part comprising up to 13 amino carboxylic residues, the C-terminal amino carboxylic thereof is recognised by FAPα, and a cytotoxic or cytostatic part, characterized in that the N-terminal amino function of the oligomeric part is attached to a capping group (Cg) which is capable of enhancing the chemical stability of said prodrug under physiological conditions and the physical stability of an aqueous pharmaceutical formulations comprising said prodrug.

A preferred embodiment of the present invention is a prodrug wherein the capping group is a group of formula R^2-$(CH_2)_m$-Z-, in which R^2 represents

(a) a group selected from C_1-C_6 alkyl, C_3-C_8 cycloalkyl, aryl and heteroaryl, wherein each of these groups is substituted by at least one amino, carboxy or hydroxy group, or

(b) an optionally substituted 5- to 7-membered saturated, unsaturated or aromatic nitrogen containing heterocyclic group, or

(c) a phenyl group which is substituted by 1 to 5 fluorine atoms;

Z represents -CO-, -O-CO-, SO_2-, NH-CO-NH or a single bond;

m is 0 r 1.

A further embodiment of the invention is a prodrug wherein the C-terminal amino carboxylic residue is selected from D-proline, L-proline, D-hydroxyproline and L-hydroxyproline and the oligomeric part comprises two, three or four amino carboxylic acid residues.

The oligomeric part is preferably a peptide. Preferably, the oligomeric part comprises two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve amino carboxylic acid residues, more preferably two, three, or four amino carboxylic residues. The N-terminal amino function is preferably protected by a capping group.

The compounds of the invention may be synthesized by processes known in the art (E. Wünsch, Synthese von Peptiden, in "Methoden der organischen Chemie", Houben-Weyl (Eds. E. Müller, O. Bayer), Vol. XV, Part 1 and 2, Georg Thieme Verlag, Stuttgart, 1974). For example, the compounds could be synthesized in a block synthetic fashion by condensation of the terminal carboxy function of the oligomeric part, wherein X may be OH or an activation leaving group, with the amino group of the cytotoxic or cytostatic molecule H_2N-Cyt' resulting in an amide formation.



If a linker residue (L) is required between the oligomeric part and the cytotoxic or cytostatic agent the block synthesis can be done in the same manner.



If the cytotoxic or cytostatic bears a carboxy function for the attachment to the oligomeric part, the linker molecule can be an amine or an amino alcohol and the block synthesis of such compounds can be carried out in a similar way by reaction of the activated XOC-Cyt' with either the hydroxy or the amino component.



If the cytotoxic or cytostatic reagent has a hydroxy function which is suitable for the coupling to the oligomeric part the linker residue may be an amino carboxylic acid and a block synthesis can be done similarly.

If necessary, other functional groups in the units Cyt', L, hydroxyproline, A, B and D which shall not react during the assembly of the target molecules may be protected by suitable protecting groups. Suitable protecting groups are well known from the state of the art (P.G.M. Wuts, "Protective groups in organic synthesis", John Wiley and Sons Inc., New York 1991). These protecting groups are removed at the end of the synthesis.

By way of example only, useful amino-protecting groups may include, for example, C_1-C_{10} alkanoyl groups such as formyl, acetyl dichloroacetyl, propionyl, 3,3-diethylhexanoyl, and the like, C_1-C_{10} alkoxycarbonyl and C_6-C_{17} aralkyloxycarbonyl groups such as *tert*-butoxycarbonyl, benzyloxycarbonyl (BOC), fluorenylmethoxycarbonyl, and the like. Most preferred is fluorenylmethoxycarbonyl (FMOC).

Suitable carboxy-protecting groups may include, for example, C_1-C_{10} alkyl groups such as methyl, tert-butyl, decyl; C_6-C_{17} aralkyl such as benzyl, 4-methoxybenzyl, diphenylmethyl, triphenylmethyl, fluorenyl; tri-(C_1-C_{10} alkyl)silyl or (C_1-C_{10} alkyl)-diarylsilyl such as tri-methylsilyl, dimethyl-*tert*-butylsilyl, diphenyl-*tert*-butylsilyl and related groups.

To achieve such ester- or amide formations, it may be necessary to activate the carbonyl group of the carboxylic acid for a nucleophilic attack of an amine or alcohol, i.e. X to be an activation group or leaving group which is suitable to be substituted by an amino group. This activation can be done by conversion of the carboxylic acid into an acid chloride or acid fluoride or by conversion of the carboxylic acid into an activated ester, for instance a N-hydroxysuccinimidyl ester or a pentafluorophenyl ester. Another method of activation is the transformation into a symmetrical or unsymmetrical anhydride. Alternatively, the formation of the amide- or ester bonds can be achieved by the use of in situ coupling reagents like benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP) (E. Frerot et al., *Tetrahedron*, 1991, 47, 259-70), 1,1'-carbonyldimidazole (CDI) (K. Akaji et al., *THL*, 35, 1994, 3315-18), 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) (R. Knorr et al., *THL*, 30, 1989, 1927-30), 1-(mesitylene-2-sulfonyl)-3-nitro-1H-1,2,4-triazole (MSNT) (B. Blankenmeyer-Menge et al., *THL*, 31, 1990, 1701-04).

As an alternative to the block synthesis the molecules in the general formula (I) can be assembled in a step by step manner starting at the right hand side by stepwise condensation reactions of the respective monomers Cyt', L, the cyclic amino acid group formed by R^a, R^b and the interjacent N-C group, in particular proline or hydroxyproline, A, B and D. For the condensation reaction the same above mentioned coupling methods can be applied. Since the units L, proline/hydroxyproline, A, B and D are at least bifunctional molecules containing an amino- and (at least the units A, B, D, and the cyclic amino acid group

formed by Ra, Rb and the interjacent N-C group, in particular proline/hydroxyproline) a carboxy group, the amino group needs to be blocked by a protecting group (PG) prior to the activation of the carboxylic function. For the protection of the amino groups the group BOC or preferably the group FMOC can be applied. After the coupling reaction the amino protecting group has to be removed and the coupling with the next Fmoc- or Boc-protected unit can be carried out. If necessary, other functional groups in the units Cyt', L, the cyclic amino acid group formed by Ra, Rb and the interjacent N-C group, in particular hydroxyproline, A, B and D which shall not react during the assembly of the target molecules may be protected by suitable protecting groups. These protecting groups are removed at the end of the synthesis.

Capping groups as defined in the context of formula (I) may also serve as protection groups, in particular when the last (N-terminal) amino carboxylic acid unit is added. In this latter case the protecting group is not removed as it is a part of the target molecule. Alternatively, the capping group may be added after the last amino carboxylic acid unit has been coupled and deprotected.

The step by step synthesis is outlined in the following schemes. The second scheme is exemplary as the linker residue as well as the Cyt' residue may contain other functional groups as indicated in this scheme (see above):





Preferably, X is a leaving group, for example –Cl, -F, N-hydroxysuccinimidyl, pentafluorophenyl, or a carboxylate. Alternatively, X^2 may be OH and condensation is achieved by the use of an in situ coupling reagent, for example benzotriazole-1-yl-oxy-tris-pyrrolidinophosphonium hexafluorophosphate (PyBOP), 1,1'-carbonyldimidazole (CDI), 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU), or 1-(mesitylene-2-sulfonyl)-3-nitro-1H-1,2,4-triazole (MSNT).

PG is a protecting group for example BOC, or preferably FMOC .

The compounds of the invention are intended for medical use. In particular, these compounds are useful for the treatment of tumors which are associated with stromal fibroblasts that express FAPα and which are generally not optimally treated with available cytotoxic and/or cytostatic agents. Tumors with this property are, for example, epithelial cancers, such as lung, breast, and colon carcinomas. Tumors, such as bone and soft tissue sarcomas which express FAPα, may also be treated with these compounds.

Consequently, another aspect of the present invention are pharmaceutical compositions comprising a compound of the present invention and optionally one or more suitable and pharmaceutically acceptable excipients, as exemplified in: *Remington: the science and practice of pharmacy. 19th ed. Easton : Mack Publ., 1995*. The pharmaceutical compositions may be formulated as solids or solutions. Solid formulations may be for preparation of a solution before injection. Preferably, the pharmaceutical compositions of the invention are solutions for injection. They may be administered systemically, e.g. by intravenous in-

jection, or topically, e.g. by direct injection into the tumor site. The dosage will be adjusted according to factors like body weight and health status of the patient, nature of the underlying disease, therapeutic window of the compound to be applied, solubility, and the like. It is within the knowledge of the expert to adjust dosage appropriately. For doxorubicin conjugates, for example, the dose will preferably be in the range from 10 mg/m^2 to 2000 mg/m^2, but also higher or lower doses may be appropriate.

Accordingly, a further aspect of the present invention is the use of a compound of the invention in the preparation of a pharmaceutical composition for the treatment of cancer. Furthermore, an aspect of the invention is a method of treatment of cancer, comprising administering an effective amount of a pharmaceutical composition of the invention to a patient. Indications include the treatment of cancer, specifically:

1) The treatment of epithelial carcinomas including breast, lung, colorectal, head and neck, pancreatic, ovarian, bladder, gastric, skin, endometrial, ovarian, testicular, esophageal, prostatic and renal origin;
2) Bone and soft-tissue sarcomas: Osteosarcoma, chondrosarcoma, fibrosarcoma, malignant fibrous histiocytoma (MFH), leiomyosarcoma;
3) Hematopoietic malignancies: Hodgkin's and non-Hodgkin's lymphomas;
4) Neuroectodermal tumors: Peripheral nerve tumors, astrocytomas, melanomas;
5) Mesotheliomas.

Also included are the treatment of chronic inflammatory conditions such as rheumatoid arthritis, osteoarthritis, liver cirrhosis, lung fibrosis, arteriosclerosis, and abnormal wound healing.

A further aspect of the invention is a method of treatment of cancer, wherein a prodrug is administered to a patient wherein said prodrug is capable of being converted into a cytotoxic or cytostatic drug by an enzymatic activity, said enzymatic activity being the expression product of cells associated with tumor tissue. Preferably, said enzymatic activity is the proteolytic activity of FAPα. The prodrug exhibits an oligomeric part comprising up to 13 amino carboxylic residues, the C-terminal amino carboxylic thereof is recognised by FAPα, and a cytotoxic or cytostatic part, characterized in that the N-terminal amino function of the oligomeric part is attached to a capping group (Cg) which is capable of

enhancing the chemical stability of said prodrug under physiological conditions and the physical stability of aqueous pharmaceutical formulations comprising said prodrug.

A further aspect of the invention is the use of a prodrug which is capable of being converted into a cytotoxic or cytostatic drug by the enzymatic activity of FAPα, said prodrug exhibiting an oligomeric part comprising up to 13 amino carboxylic residues, the C-terminal amino carboxylic thereof is recognised by FAPα, and having a cytotoxic or cytostatic part, wherein the N-terminal amino function of the oligomeric part is attached to a capping group (Cg) which is capable of enhancing the chemical stability of said prodrug under physiological conditions and the physical stability of aqueous pharmaceutical formulations comprising said prodrug, for the manufacture of a stable medicament for the treatment of cancer.

One method of administration of the compounds is intravenous infusion. Other possible routes of administration include intraperitoneal (either as a bolus or infusion), intramuscular or intratumoral injection. Where appropriate, direct application may also be possible (for example, lung fibrosis).

One skilled in the art will appreciate that although specific reagents and reaction conditions are outlined in the following examples, modifications can be made which are meant to be encompassed by the scope of the invention. The following examples, therefore, are intended to further illustrate the invention and are not limiting.

Example 1

Synthesis of 3,5-Difluorophenylacetyl-Gly-Pro-OH

H-Pro-2-chlorotritylchloride-resin (200 mg, 0.158) was added to a reaction vessel and washed with DMF (three times with 7 ml). Fmoc-Gly-OH (284.4 mg, 0.95 mmol), HOBt (128.1, 0.95 mmol), DIC (146.8 µl, 0.95 mmol) and DMF (6 ml) were added to the reaction vessel. After 6 h of agitation, the resin was then filtered, washed with DMF (eight times with 7 ml) and 20% piperidine in DMF (4 ml) was added to the reaction vessel. After agitation for 30 min, the resin was filtered and washed with DMF (eight times with 7 ml). 3,5-Difluorophenylacetic acid (163.2 mg, 0.95 mmol), 1-hydroxybenzotriazole (HOBt) (128.1, 0.95 mmol), diisopropylcarbodiimide (DIC) (146.8 µl, 0.95 mmol) and N,N dimethylformamide (DMF) (6 ml) were added to the reaction vessel. After 12 h of agitation, the resin was washed with DMF (six times with 7 ml), dichloromethane (DCM) (six times with 7 ml), methanol (MeOH) (six times with 7 ml), and Et_2O (six times with 7 ml) and treated with a solution of trifluoroacetic acid/water 95:5 (6 ml). After incubation for 2 h, the cleavage solution was placed into a flask and the resin was washed additionally with DCM (twice with 3 ml).

The cleavage solution was removed with a roto-evaporator and the resulting oil was dried with a stream of nitrogen. The crude product was purified by preparative reversed phase HPLC applying a acetonitrile/water gradient. The product gave satisfactory analytical data. HPLC > 95 %; ES-MS: m/z = 326.3 ($[M+H]^+$)

Examples 2 to 6

The following N-terminal blocked peptides were prepared analogously to this method:

Example	Compound
2	
3	
4	
5	
6	

Example 7

Synthesis of Pyridin-3-ylmethoxycarbonyl-Pro-Ala-Gly-Pro-OH

H-Pro-2-chlorotritylchloride-resin (200 mg, 0.158) was added to a reaction vessel and washed with DMF (three times with 7 ml). Fmoc-Gly-OH (284.4 mg, 0.95 mmol), HOBt (128.1, 0.95 mmol), DIC (146.8 µl, 0.95 mmol) and DMF (6 ml) were added to the reaction vessel. After 6 h of agitation, the resin was then filtered, washed with DMF (eight times with 7 ml) and 20% piperidine in DMF (4 ml) was added to the reaction vessel. After agitation for 30 min, the resin was filtered and washed with DMF (eight times with 7 ml).

Fmoc-Ala-OH and Fmoc-Pro-OH were incorporated in the same manner. The Fmoc-group of proline was removed and the resin was washed with DMF (eight times with 7 ml)and DCM (six times with 7 ml). 3-Pyridylcarbinol (99 µl, 0.25 mmol) was treated with 4-nitrophenyl chloroformate (156 mg, 0.20 mmol) and triethylamine (225 µl, 0.4 mmol) in DCM (7 ml) for 6 h and the resulting mixture was added to the resin. After 12 h of agitation, the resin was washed with DCM (six times with 7 ml), MeOH) (six times with 7 ml), and Et_2O (six times with 7 ml) and treated with a solution of trifluoroacetic acid/water 95:5 (6 ml). After incubation for 2 h, the cleavage solution was placed into a flask and the resin was washed additionally with DCM (twice with 3 ml).

The cleavage solution was removed with a roto-evaporator and the resulting oil was dried with a stream of nitrogen. The crude product was purified by preparative reversed phase HPLC applying a acetonitrile/water gradient. The product gave satisfactory analytical data. HPLC > 95 %; ES-MS: m/z = 475.5 ($[M+H]^+$)

Examples 8 to 10

The following blocked peptides have been prepared analogously.

Example	Compound
8	
9	
10	

Example 11

Synthetic procedures of doxorubicin conjugates

11 Pyridin-3-ylmethoxycarbonyl-Pro-Ala-Gly-Pro-Doxorubicin

Pyridin-3-ylmethoxycarbonyl-Pro-Ala-Gly-Pro-OH (180.7 mg, 0.38 mmol) and N-hydroxysuccinimide (44 mg, 0.37 mmol) were weighed out and placed in a 2 neck-round bottom flask under dinitrogen. Anhydrous *N,N*-dimethylformamide (20 ml) was added and the flask was cooled to 0 °C in an ice bath. Dicyclohexylcarbodiimide (78 mg, 0.38 mmol) was added as a 1 ml solution in N,N-dimethylformamide. The solution was stirred at 0 °C for 40 minutes.

Doxorubicin•HCl (100 mg, 0.38 mmol) was weighed into a separate vial. *N,N*-dimethylformamide (3 ml) and *N,N*-Diisopropylethylamine (33.1 µl, 0.19 mmol) were added to the vial with stirring. The doxorubicin solution was added *via* syringe to the peptide solution, and the vial was rinsed with an additional 2 ml of *N,N*-dimethylformamide. The ice bath was removed and reaction mixture was stirred for approximately 48 hours at room temperature.

The solvent was removed with a roto-evaporator and the resulting oil was dried with a stream of nitrogen. The crude product was purified by preparative reversed phase HPLC applying a acetonitrile/water gradient. The product gave satisfactory analytical data. HPLC > 95 %; ES-MS: m/z = 1002 ($[M+H]^+$)

Examples 12 to 20

Analogously are obtained the following doxorubicin conjugates of formula



Example	R^1

12



13



14



15



16



17



18



19



20



Example 21

Preparation of FAPα-expressing cell lines

Mammalian cell lines expressing recombinant FAPα were prepared. HT1080 fibrosarcoma cells, widely known and available from the DSMZ (German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany) under the accession number DSMZ ACC 315, were maintained in a DMEM/F12 mix 50:50 containing 10% fetal bovine serum in an atmosphere of 95% air and 5% CO_2. HT1080 cells were transfected with FAP.38 vector (WO 97/34927, Scanlan *et al., loc. cit.*) using the Lipofectin method according to the manufacturer's instructions (Gibco/BRL). Transfectants were selected for resistance to antibiotics (200 ug/ml Geneticin) and thereafter maintained in medium containing Geneticin. Individual colonies of resistant cells were picked, grown to confluence in 10 cm tissue culture petri dishes and tested for FAPα expression in an immunofluorescence assay using the FAPα-specific monoclonal antibody F19, as described (Garin-Chesa *et al.* (1990) *Proc. Natl. Acad. Sci. USA* **87**(18), 7235-7239). The parental HT1080 cell line showed no detectable FAPα expression in this immunofluorescence assay, while one clone, referred to hereafter as HT1080 clone 33, was positive for FAPα.

Similarly, human embryonic kidney 293 cells, widely known and available from American Tissue Type Collection (Rockville, MD), were maintained in a DMEM containing 10% fetal bovine serum in an atmosphere of 95% air and 5% CO_2. Cells were transfected with a FAPα expression vector, pFAP.38 using calcium phosphate transfection as described (Park, J. E., Chen, H. H., Winer, J., Houck, K. A. & Ferrara, N. (1994). Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. *J. Biol. Chem.* **269**(41), 25646-25654). Transfectants were selected and analyzed as described above for FAPα expression. The parental 293 cell line showed no detectable FAPα expression. One clone, referred to hereafter as 293-I/2, was FAPα positive.

Example 22

Examination of FAPα expression in transfected cell lines

FAPα expression was examined in the HT1080 and HT1080 clone 33 cells. Metabolic labeling, immunoprecipitations and fluorography were performed essentially as described

(Park et al. (1991) *Somatic Cell Mol. Genet.* **17**(2), 137-150). HT1080 and HT1080 clone 33 cells were metabolically labelled with ^{35}S-methionine. Detergent extracts of these cells were immunoprecipitated with monoclonal antibody F19 or with mouse IgG1 antibody as a negative control. Precipitates were boiled in sample buffer and separated by sodium dodecyl sulfate gel electrophoresis (as described by Laemmli (1970) *Nature* **227**(259), 680-685). Fluorographic analysis of the resulting gel confirmed that the HT1080 clone 33 cells produce FAPα protein. No FAPα protein was detectable in extracts of the parental HT1080 cells nor in immunoprecipitates with mouse IgG1.

Example 23

Soluble recombinant FAPα

A soluble recombinant form of FAPα protein was prepared as follows. A cDNA encoding the extracellular domain (ECD) of murine CD8α (Genbank M12825), consisting of the N-terminal 189 amino acids of CD8α, was ligated to a cDNA encoding the extracellular domain of FAPα (amino acids 27 to 760), generating a fusion protein construct, FAPmCD8, similar in structure to the CD8α-CD40 ligand fusion protein, as previously described (Lane et al. (1993) *J. Exp. Med.* 177(4), 1209-1213). The cDNAs were verified by sequencing and inserted into the pVL1393 vector. Transfection of Sf9 cells and amplification of the resulting recombinant baculovirus were performed as described (O'Reilly (1994) *Baculovirus Expression Vectors: A Laboratory Manual*, Oxford University Press, New York). The culture supernatant of High Five cells infected with recombinant FAPmCD8 baculovirus for four days was collected and cleared by ultracentrifugation. FAPmCD8 fusion protein was purified from such supernatants using an anti-FAPα monoclonal antibody immobilized on activated agarose beads (Pierce Chemical, Indianapolis, IN, USA). The culture supernatant was passed through the antibody affinity column and eluted by pH shift using 0.1 M citrate buffer, pH 3. The samples were immediately neutralized with a saturated Tris solution (Sigma Chemicals, St. Louis, MO) and protein-containing fractions were pooled.

Example 24

Measurement of cleavage of doxorubicin-peptide conjugates

Samples were separated by reversed-phase high performance liquid chromatographic (HPLC) assay that was established to measure cleavage of doxorubicin-peptide conjugates. The HPLC system consisted of a Waters 717 autosampler equipped with a 100 microliter (μl) loop and two Waters model 510 pumps to deliver solvents. Separations were performed under isocratic conditions at a flow rate of 0.7 ml/min on a Nucleosil C-18 column, 100 mm long x4 mm I.D. with 5 μm particle size (Dr. Ing. H. Knauer GmbH, Berlin). The mobile phase consisted of methanol:water (70:30, v/v) containing 0.2 M ammonium acetate, adjusted to pH 3.2. Free doxorubicin and doxorubicin-peptide conjugates were detected by fluorescence (excitation, 475 nm; emission, 585 nm) using a Waters 474 fluorescence detector. Injection, solvent delivery, data acquisition, and data analysis were all performed using the Millennium 2010 chromatography software package (Waters Corp., Milford, MA, USA). Substances to be tested were first dissolved in dimethyl sulfoxide at a concentration of 5 mM and subsequently diluted in aqueous solution before being applied to the HPLC column.

The ability of soluble recombinant FAPα enzyme to release free doxorubicin from doxorubicin-peptide conjugates was examined. Doxorubicin-peptide conjugate stock solutions (5 mM) were diluted with Hepes-buffered saline pH 7.4 to a final concentration of 50 to 100 μM. Twenty μl of the resulting solution was mixed with 50 μl of purified FAPmCD8 fusion protein (approximately 20 ng) described above and 30 μl Hepes-buffered saline, pH 7.4. The mixture was allowed to incubate at 37° C for 1 day and release of free doxorubicin was measured in the HPLC assay described. Areas under each peak were quantified using the software package above and the initial value was set to 100%. The rate of release of free doxorubicin was measured by the appearance of a peak with the same retention time as free doxorubicin under these HPLC conditions. The areas under each peak were used to calculate the relative amounts of free doxorubicin to doxorubicin-peptide conjugate. Integration of peak areas to determine percent cleavage was carried out using the Millennium 2010 chromatography software package above. The doxorubicin-peptide conjugate could be converted to free doxorubicin after incubation with purified FAPmCD8 fusion protein but the retention time of the conjugate was not altered by incubation with buffer.

Example 25

Reduction of cytotoxicity of doxorubicin by conjugation to FAPα-cleavable peptides

The ability of FAPα-cleavable peptides to block the cytotoxic action of doxorubicin on FAPα-negative, doxorubicin-sensitive cells was determined. K562 cells, available from American Type Tissue Culture Collection, Rockville, MD, USA (ATCC Number: CCL-243), were seeded in 96 well plates (Greiner Scientific) at a density of 1000 cells / well. Serum-free cell culture media containing various concentrations of free doxorubicin or equivalent molar concentrations of doxorubicin-peptide conjugates were added to the cells. Four days later, cell number was determined using an automated CASY™ cell counter (Schärfe System GmbH, Reutlingen, Germany).

Example 26

Release of free doxorubicin by cell-bound FAPα

The ability of cell-bound FAPα enzyme to release free doxorubicin from doxorubicin-peptide conjugates was examined. Each conjugate was dissolved in serum-free cell culture medium at a final concentration of 1 μM. Ten milliliters of this solution was added to confluent monolayers of HT1080 or HT1080 clone 33 cells in 10 cm tissue culture dishes for 19 hours at 37° C. The media were removed and release of doxorubicin measured as described in Example 5. The FAP-expressing cell line, HT1080 clone 33, converted the conjugates of examples 11 to 20 to free doxorubicin in high percentages.

Example 27

Killing of sensitive cells by FAPα-released doxorubicin

The ability of FAPα to generate free doxorubicin capable of killing doxorubicin-sensitive cells was determined. K562 cells, available from American Type Tissue Culture Collection, Rockville, MD, USA (ATCC Number: CCL-243), were seeded in 96 well plates (Greiner Scientific) at a density of 1000 cells / well. Serum-free cell culture media containing 1 μM doxorubicin-peptide conjugate was added to HT1080 or HT1080 clone 33 cells dishes for 19 hours at 37° C. The media were removed and release of doxorubicin was confirmed as in Example 5. Sixty-six μl of this medium was then added per well to the

K562 cells. Four days later, cell number was determined using an automated CASY™ cell counter.

Example 28

Plasma stability of doxorubicin-peptide conjugates

The plasma stability of doxorubicin-peptide conjugates was measured using methods described in Example 24. Samples containing doxorubicin-peptide conjugates (at a concentration of 1 μM) were incubated in the presence of 10% (v/v) mouse or human plasma for the times indicated at 37° C.

FAPα-catalyzed cleavage of selected 4-methoxy-β-napthylamide-peptide conjugates

To identify preferred FAPα peptide substrates, blocked oligopeptides composed of natural amino carboxylic acids were synthesized and coupled to Proline-4-methoxy-β-napthylamine (Pro-MNA) using methods known to the art (E. Wünsch, Synthese von Peptiden, in Methoden der organischen Chemie, Houben-Weyl (Eds. E. Müller, O. Bayer), Vol. XV, Part 1 and 2, Georg Thieme Verlag, Stuttgart, 1974). The turnover and cleavage rate have been determined with the aid of the following assay:

Assay for cleavage of MNA substrates by FAP:

Buffer A:

100mM Tris HCl pH 7.8, 100 mM NaCl

Cell extract from 293 cells stably transfected with FAP prepared as described (see Park, et al., Fibroblast Activation Protein, a Dual Specificity Serine Protease expressed in human tumor stromal fibroblasts. (1999) J. Biol. Chem. 36505-12.). A similar extract was also prepared from parental 293 control cells without FAP. The FAP concentration in the FAP-transfected cell extract was estimated by immunoassay and 1 ng enzyme (diluted in buffer A) was used per assay. FAP-negative 293 control cell extract was used at the same dilution (also in buffer A) as a negative control. Substrate was initially dissolved in dimethylformamide at a concentration of 200 mM and diluted in buffer A to a final concentration of 2.5 mM. A few substrates were not soluble at this concentration and had to be diluted further.

Assay conditions:

10 µl 10% DMSO in buffer A

70 µl diluted FAP cell extract containing 1 ng FAP enzyme (OR control 293 cell extract without FAP)

20 µl 2.5 mM substrate

Mix, incubate at room temperature for 1 hour, and measure fluorescence in Fluorostar fluorimeter at the following wavelengths:

MNA conjugates: Excitation: 355 nm, Emission: 405 nm.

The fluorescence measured in the samples treated with control 293 control cell extracts without FAP is subtracted from the values measured in the samples treated with 1 ng FAP enzyme.

Example 29

Synthesis of 3,5-Difluorophenylacetyl-Gly-OH

H-Gly-Wang-resin (200 mg, 0.158) was added to a reaction vessel and washed with DMF (three times with 7 ml). 3,5-Difluorophenylacetic acid (163.2 mg, 0.95 mmol), 1-hydroxybenzotriazole (HOBt) (128.1, 0.95 mmol), diisopropylcarbodiimide (DIC) (146.8 µl, 0.95 mmol) and N,N dimethylformamide (DMF) (6 ml) were added to the reaction vessel. After 12 h of agitation, the resin was washed with DMF (six times with 7 ml), dichloromethane (DCM) (six times with 7 ml), methanol (MeOH) (six times with 7 ml), and Et_2O (six times with 7 ml) and treated with a solution of trifluoroacetic acid/water 95:5 (6 ml). After incubation for 2 h, the cleavage solution was placed into a flask and the resin was washed additionally with DCM (twice with 3 ml).

The cleavage solution was removed with a roto-evaporator and the resulting oil was dried with a stream of nitrogen. The crude product was purified by preparative reversed phase HPLC applying a acetonitrile/water gradient. The product gave satisfactory analytical data.

HPLC > 95 %; ES-MS: m/z = 219.2 ($[M+H]^+$)

Examples 30 to 34

The following N-terminal blocked glycine amino acids were prepared analogously to this method:

Example	Compound
30	
31	
32	
33	
34	

Example 35

Synthesis of Pyridin-3-ylmethoxycarbonyl-Pro-Ala-Gly-OH

H-Gly-Wang-resin (200 mg, 0.158) was added to a reaction vessel and washed with DMF (three times with 7 ml). Fmoc-Ala-OH (295.7 mg, 0.95 mmol), HOBt (128.1, 0.95 mmol), DIC (146.8 µl, 0.95 mmol) and DMF (6 ml) were added to the reaction vessel. After 6 h of agitation, the resin was then filtered, washed with DMF (eight times with 7 ml) and 20% piperidine in DMF (4 ml) was added to the reaction vessel. After agitation for 30 min, the resin was filtered and washed with DMF (eight times with 7 ml). Fmoc-Pro-OH was incor-

porated in the same manner. The Fmoc-group of proline was removed and the resin was washed with DMF (eight times with 7 ml)and DCM (six times with 7 ml). 3-Pyridylcarbinol (99 µl, 0.25 mmol) was treated with 4-nitrophenyl chloroformate (156 mg, 0.20 mmol) and triethylamine (225 µl, 0.4 mmol) in DCM (7 ml) for 6 h and the resulting mixture was added to the resin. After 12 h of agitation, the resin was washed with DCM (six times with 7 ml), MeOH) (six times with 7 ml), and Et_2O (six times with 7 ml) and treated with a solution of trifluoroacetic acid/water 95:5 (6 ml). After incubation for 2 h, the cleavage solution was placed into a flask and the resin was washed additionally with DCM (twice with 3 ml).

The cleavage solution was removed with a roto-evaporator and the resulting oil was dried with a stream of nitrogen. The crude product was purified by preparative reversed phase HPLC applying a acetonitrile/water gradient. The product gave satisfactory analytical data.

HPLC > 95 %; ES-MS: m/z = 378.4 ($[M+H]^+$)

Example 29

Synthesis of Pyridin-3-ylmethoxycarbonyl-Pro-Ala-Gly-Pro-MNA

Pyridin-3-ylmethoxycarbonyl-Pro-Ala-Gly-OH (51.8 mg, 0,11 mmol), H-Pro-MNA (33.4 mg, 0.11 mmol), O-(benzotriazo-1-yl)-N,N,N',N',-tetramethyluronium-hexafluorophosphate (TBTU) (34.9 mg, 0.13 mmol), HOBt (14.7 mg, 0.11 mmol) and N-ethyldiisopropylamine (DIEA) (55.8 ml, 0.11 mmol) were dissolved in anhydrous DMF and stirred at 25°C for 12 h. The solvent was then removed with a roto evaporator and the product was dissolved in DCM (10 ml). The DCM solution was washed with saturated aqueous sodium bicarbonate (30 ml) and brine (30 ml). The organic extract was dried with anhydrous $MgSO_4$, and the solvent was removed with a roto-evaporator. The product was chromatographed by preparative RP-HPLC on C18 using a gradient of water/acetonitrile with 0.1% trifluoroacetic acid.

HPLC > 95 %; ES-MS: m/z = 631 ($[M+H]^+$)

The following table shows the peptide-MNA-conjugates which have been prepared analogously and includes cleavage data by FAP.

MNA-Conjugate	% Turnover	Cleavage [µM]
4-Amino-Phenylacetyl-Gly-Pro-MNA	0.6	3
3,5-Difluorphenylacetyl-Gly-Pro-MNA	2.26	2.26
2-Fluorphenylacetyl-Gly-Pro-MNA	0.26	1.28
3-Fluorphenylacetyl-Gly-Pro-MNA	0.35	1.77
4-Fluorphenylacetyl-Gly-Pro-MNA	0.42	2.08
3-Pyridylacetyl-Gly-Pro-MNA	1.82	9.12
3-Pyridylmethyloxycarbonyl-Gly-Pro-MNA	0.72	3.58
4-Pyridylmethyloxycarbonyl-Gly-Pro-MNA	1.18	5.92
3-Pyridylmethyloxycarbonyl-Pro-Ala-Gly-Pro-MNA	1.77	8.86
4-Pyridylmethyloxycarbonyl-Pro-Ala-Gly-Pro-MNA	1.28	6.38

Example 36

Preparation of Pyridin-3-ylmethoxycarbonyl-Pro-Ala-Gly-Pro-Melphalan



Pyridin-3-ylmethoxycarbonyl-Pro-Ala-Gly-Pro-OH (0.072 mmol) was dissolved in anhydrous N,N-dimethylformamide (8 ml) and pH was adjusted to 7.5 by N,N-diisopropylethylamine. N-hydroxysuccinimide (0.072 mmol) was added and the mixture was cooled in an ice bath. Under stirring, dicyclohexylcarbodiimide (0.67 mmol) was added and the solution was stirred at 0°C for 2 h.

Melphalan (0.048 mmol) was dissolved in 30 ml anhydrous DMF and N,N-diisopropylethylamine (0.072 mmol) was added. This mixture was syringed to the activated peptide. The reaction was allowed to warm up to room temperature and was stirred for 24 h. The solvent was then removed and the product was purified by preparative RP-HPLC on C18 using a gradient of water/acetonitrile with 0.1% trifluoracetic acid.

Claims

1. A compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof,

wherein

R^1 represents an amino alkanoyl or oligopeptidoyl group, the N-terminal amino function of which is attached to a capping group (Cg) which is capable of enhancing the chemical stability of said compound under physiological conditions and the physical stability of aqueous pharmaceutical formulations comprising said compound;

R^a and R^b together with the interjacent N-C group form an optionally substituted, optionally benzo- or cyclohexano-condensed 3- to 7-membered saturated or unsaturated heterocyclic ring, in which one or two CH_2 groups may also be replaced by NH, O or S;

R^3 represents H, C_1-C_6-alkyl, C_3-C_8-cycloalkyl, aryl or heteroaryl; and

Cyt' represents the residue of a cytotoxic or cytostatic compound.

2. A compound of formula (I) according to claim 1 wherein the capping group exhibits one or more functional groups, which have the capability of forming salts with pharmaceutially acceptable acids or bases, selected from amino, carboxy, phospate, phophonate, sulfate and sulfonate groups.

3. A compound of formula (I) according to claim 1 or 2, wherein

said capping group (Cg) is a group of formula

$$R^2\text{-}(CH_2)_m\text{-}Z\text{-},$$

in which

R^2 represents

(a) a group selected from C_1-C_6 alkyl, C_3-C_8 cycloalkyl, aryl and heteroaryl, wherein each of these groups is substituted by at least one amino, carboxy, phospate, phophonate, sulfate, sulfonate or hydroxy group, or

(b) an optionally substituted 5- to 7-membered saturated or unsaturated nitrogen, oxygen and/or sulfur containing heterocyclic group,

(c) a phenyl group which is substituted by 1 to 5 fluorine atoms;

(d) a C_1-C_6 fluoroalkyl group; or

(e) in the case that m is1, an optionally substituted 5- to 6-membered heteroaryl group;

Z represents –CO-, -O-CO-, -SO_2-, NH-CO-NH or a single bond;

m is 0 or 1.

4. A compound of formula (I) according to claim 1 or 2, wherein

R^1 represents a residue of formula Cg-A, Cg-B-A or Cg-$(D)_n$-B-A, in which

Cg represents a capping group of formula R^2-$(CH_2)_m$-Z-, wherein R^2 is an optionally substituted saturated heterocyclyl or heteroaryl group;

m is 0 or 1;

A, B and D each independently represent moieties derived from amino carboxylic acids of the formula -[NR^4-$(X)_p$-CO]- wherein X represents CR^5R^6 and wherein R^4, R^5 and R^6 each independently represent a hydrogen atom, an optionally substituted C_1-C_6-alkyl, C_3-C_8-cycloalkyl, aryl, aralkyl, heteroaryl or heteroarylalkyl group, and

p is 1, 2, 3, 4, 5; or

A, B and D each independently represent moieties derived from cyclic amino carboxylic acids of formula



wherein

R^7 represents C_1-C_6-alkyl, OH, or NH_2,

n is an integer from 1 to 10;

q is 0, 1 or 2; and

r is 0, 1 or 2.

5. A compound of formula I according to any of claims 1 to 3, wherein the heterocyclic ring formed by R^a, R^b and the interjacent N-C is substituted by R^8 and R^9, wherein R^8 and R^9 each independently represent a hydrogen or halogen atom or a C_1-C_6-alkyl, C_1-C_6-alkylamino, di-C_1-C_6-alkylamino, C_1-C_6-alkoxy, thiol, C_1-C_6-alkylthio, oxo, imino, fomyl, C_1-C_6-alkoxy carbonyl, amino carbonyl, C_3-C_8-cycloalkyl, aryl, or heteroaryl group.

6. A compound of fomula IA



(IA)

wherein R^1, R^3, R^8, Cyt' are as defined in any of the preceding claims, and X-Y represents CHR^9-CH_2, CR^2=CH, NH-CH_2, CH_2-NH, -CR^9-, CH_2-CHR^9-CH_2.

7. A compound of fomula IA1



(IA1)

wherein R^3, Cyt' Cg, X and Yare as defined in any of the preceding claims, and R^{10} and R^{11} each independently represent a hydrogen atom, an optionally substituted C_1-C_6-alkyl, C_3-C_8-cycloalkyl, aryl or heteroaryl group, or
R^{10} and R^{11} together with the interjacent N-C group form an optionally substituted, optionally benzo- or cyclohexano-condensed 3- to 7-membered saturated or unsaturated heterocyclic ring, in which one or two CH_2 groups may also be replaced by NH, O or S.

8. A compound of fomula IA2



(IA2)

wherein R^3, Cyt' Cg, X and Yare as defined in any of the preceding claims, and

R^{10} and R^{11} each independently represent a hydrogen atom, an optionally substituted C_1-C_6-alkyl, C_3-C_8-cycloalkyl, aryl or heteroaryl group or
R^{10} and R^{11} together with the interjacent N-C group form an optionally substituted, optionally benzo- or cyclohexano-condensed 3- to 7-membered saturated or unsaturated heterocyclic ring.

9. Compounds of formulae I, IA, IA1 or IA2 according to any of the preceding claims, wherein
R^2 represents a group selected from



10. A compound according to any of the preceding claim, wherein R^1 represents an aminoalkanoyl, or an oligopeptidoyl group, which is derived from glycine (Gly), or the D- or L-forms of alanine (Ala), valine (Val), leucine (Leu), isoleucine (Ile), phenylalanine (Phe), tyrosine (Tyr), tryptophan (Trp), cysteine (Cys), methionine (Met), serine (Ser), threonine (Thr), lysine (Lys), arginine (Arg), histidine (His), aspartic acid (Asp), glu-

tamic acid (Glu), asparagine (Asn), glutamine (Gln), proline (Pro), 4-hydroxy-proline (Hyp), 5-hydroxy-lysine, norleucine (Nle), 5-hydroxynorleucine (Hyn), 6-hydroxynorleucine, ornithine, or cyclohexylglycine (Chg) and wherein the N-terminal amino function of said aminoalkanoyl or oligopeptidoyl group is attached to a capping group Cg.

11. A compound of formula I according to any of the preceding claims, wherein the unit A is derived from L-proline, glycine, L-norleucine, L-cyclohexylglycine, L-5-hydroxynorleucine, L-6-hydroxynorleucine, L-5-hydroxylysine, L-arginine, or L-lysine.

12. A compound according to any of the preceding claims wherein R^1 is a group selected from the formulae (1) to (14):

Cg-Gly	(15)
Cg-Nle	(16)
Cg-Val	(17)
Cg-Met	(18)
Cg-Xxx-Gly	(19)
Cg-Xxx-Hyn	(20)
Cg-Xxx-Pro	(21)
Cg-Xxx-His	(22)
Cg-Xxx-Met	(23)
Cg-Xxx-Ala	(24)
Cg-Xxx-Hyn	(25)
Cg-Xxx-Ala-Gly	(26)
Cg-$(Xxx)_n$-Xxx-Gly	(27)
Cg-$(Xxx)_n$-Xxx-Ala-Gly	(28)

wherein

Cg represents a capping group selected from pyridinyloxycarbonyl, pyridinylacetyl, pyridinylmethylsulfonyl and pyridylmethylaminocarbonyl;

Xxx represents a moiety derived from an amino carboxylic acid; and

n is an integer from 1 to 6.

13. A compound according to claim 11 wherein the amino alkanoic acid moieties exist in the (L)-configuration

14. A compound of any one of claims 1 to 12, wherein Cyt' is an anthracycline group.

15. A compound of claim 13 selected from the formulae (IIIA) to (IIIF):



(IIIA)



(IIIB)



(IIIC)



(IIIE)



(IIIF)

15. A prodrug that is capable of being converted into a cytotoxic or cytostatic drug, by the catalytic action of FAPα, and which includes oligomeric part having an N-terminal amino function and a C-terminal amino carboxylic function and comprising up to 13

amino carboxylic residues, the C-terminal amino carboxylic thereof is recognised by FAPα, and which includes a cytotoxic or cytostatic part, characterized in that

the N-terminal amino function of the oligomeric part is attached to a capping group (Cg) which is capable of enhancing the chemical stability of said prodrug under physiological conditions and the physical stability of an aqueous pharmaceutical formulations comprising said prodrug.

16. The prodrug of claim 15 wherein the capping group is a group of formula R^2-$(CH_2)_m$-Z-, in which R^2 represents

(a) a group selected from C_1-C_6 alkyl, C_3-C_8 cycloalkyl, aryl and heteroaryl, wherein each of these groups is substituted by at least one amino, carboxy or hydroxy group, or

(b) an optionally substituted 5- to 7-membered saturated, unsaturated or aromatic nitrogen containing heterocyclic group, or

(c) a phenyl group which is substituted by 1 to 5 fluorine atoms;

Z represents –CO-, -O-CO-, -SO2-, NH-CO-NH or a single bond;

m is 0 or 1.

17. The prodrug of claim 15 or 16, wherein the C-terminal amino carboxilic residue is selected from D-proline, L-proline, D-hydroxyproline and L-hydroxyproline and the oligomeric part comprises two, three, or four amino carboxylic acid residues.

18. A compound of any one of the preceding claims for medical use.

19. Pharmaceutical composition comprising a compound according to any one of claims 1 to 18, and optionally one or more pharmaceutically acceptable carriers, diluents or excipients.

20. Use of a compound according to any one of claims 1 to 18 in the preparation of a pharmaceutical composition for the treatment of cancer.

21. Method of treatment of cancer, comprising administering a pharmaceutical composition according to claim 19 to a patient.

22. Method of treatment of cancer, wherein a prodrug is administered to a patient wherein said prodrug is capable of being converted into a cytotoxic or cytostatic drug by the enzymatic activity of FAPα, and said prodrug exhibits an oligomeric part comprising up to 13 amino carboxylic residues, the C-terminal amino carboxylic thereof is recognised by FAPα, and a cytotoxic or cytostatic part, characterized in that the N-terminal amino function of the oligomeric part is attached to a capping group (Cg) which is capable of enhancing the chemical stability of said prodrug under physiological conditions and the physical stability of aqueous pharmaceutical formulations comprising said prodrug.

23. Use of a prodrug which is capable of being converted into a cytotoxic or cytostatic drug by the enzymatic activity of FAPα, said prodrug exhibits an oligomeric part comprising up to 13 amino carboxylic residues, the C-terminal amino carboxylic thereof is recognised by FAPα, and a cytotoxic or cytostatic part, wherein the N-terminal amino function of the oligomeric part is attached to a capping group (Cg) which is capable of enhancing the chemical stability of said prodrug under physiological conditions and the physical stability of aqueous pharmaceutical formulations comprising said prodrug, for the manufacture of a stable medicament for the treatment of cancer.

Abstract

The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAPα), said prodrug is chemically stable under physiological conditions and can be used for the manufacture of physically stable aqueous formulations. It has a cleavage site which is recognised by FAPα, and the drug released by the enzymatic activity of FAPα is cytotoxic or cytostatic under physiological conditions.